Critical Appraisal of Neuroprotection Trials in Head Injury: What Have We Learned?
AUTOR(ES)
Tolias, Christos M.
FONTE
The American Society for Experimental NeuroTherapeutics
RESUMO
Summary: To date, despite very encouraging preclinical results, almost all phase II/III clinical neuroprotection trials in traumatic brain injury (TBI) have failed to show any consistent improvement in outcome for TBI patients. To understand the reasons behind such developments we need to review and evaluate the evolution of trial design as a result of our changing understanding of the pathophysiology of brain cell death and progress of translational research from the laboratory bench to the bedside. This paper attempts to critically appraise these neuroprotection trials, rationalize the paucity of effectiveness, review any recent developments in the field, and try to draw some conclusions on how to move forward.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=534913Documentos Relacionados
- Asthma Therapies Revisited: What Have We Learned?
- The pilocarpine model of epilepsy: what have we learned?
- Managing congestive heart failure medically--what have we learned?
- Immune-checkpoint inhibitors for glioblastoma: what have we learned?
- The SARS epidemic in Hong Kong: what lessons have we learned?
